GPRC5D and Miyoshi myopathy: In preclinical studies, BCMA/GPRC5D and BCMA/CS1 bispecific CAR-T cells showed robust anti-tumor activities against MM cells, and they could overcome BCMA-negative antigen escape (36, 37).